Lanreotide diTFA
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome.
For research use only. We do not sell to patients.
- CAS No.: 1024499-83-9
- Formula: C58H71F6N11O14S2
- Molecular Weight:1324.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Lanreotide (BIM 23014) (100? nM; 0-48 h) enhanced radiation-induced apoptosis[1].
Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57?nM[1].
Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:GH3
-
Concentration:100 nM
-
Incubation Time:48 h, 24 h, or immediately (0 h) before radiation
-
Result:Increased apoptotic sub-G1 proportion compared with radiation alone.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1]
-
Dosage:2.5, 5, 10 mg/kg
-
Administration:Subcutaneous; daily for 5 days
-
Result:Produced tumor growth inhibition.
Chemical Information
-
CAS No. 1024499-83-9
-
Molecular Weight 1324.37
-
Formula C58H71F6N11O14S2
-
Synonyms
BIM 23014 diTFA
-
Sequence Shortening
{d-2nal}-CY-{d-Trp}-KVCT-NH2 (Disulfide bridge: Cys2-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [Content Brief]
[2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lanreotide diTFA Related Classifications
HY-P1959B Related Classifications
Powered by Bioz